Your browser doesn't support javascript.
loading
Chronic oral graft-versus-host disease: induction and maintenance therapy with photobiomodulation therapy.
Epstein, Joel B; Raber-Durlacher, Judith E; Epstein, Geena L; Hazenberg, Mette D; Tzachanis, Dimitrios; Spielberger, Ricardo T.
Afiliación
  • Epstein JB; City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA. jepstein@coh.org.
  • Raber-Durlacher JE; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Health Center, Los Angeles, CA, 90048, USA. jepstein@coh.org.
  • Epstein GL; Department of Oral Medicine, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Amsterdam, Netherlands.
  • Hazenberg MD; Department of Oral and Maxillofacial Surgery, Amsterdam UMC, University of Amsterdam, 1100 DD, Amsterdam, Netherlands.
  • Tzachanis D; , Beverly Hills, USA.
  • Spielberger RT; Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Support Care Cancer ; 29(3): 1387-1394, 2021 Mar.
Article en En | MEDLINE | ID: mdl-32666212
This study presents follow-up of a prior study of patients with chronic symptomatic oral chronic graft-versus-host-disease (cGVHD) managed with photobiomodulation therapy (PBM therapy for 1 month. Here, we report long-term follow-up of a series of patients where PBM therapy in patients with oral cGVHD for maintenance follows the initial period of PBM therapy for continuing management. PATIENTS AND METHODS: We report continuing follow-up of 7 cases of oral cGVHD that were treated with PBM therapy. PBM therapy was continued in these patients with the goal of determining the best management schedule of PBM to maintain or improve control of each patient's symptoms and signs of oral cGVHD. RESULTS: Oral sensitivity and mucosal changes of cGVHD were controlled with a continuing schedule of PBM therapy of up to 6-8-week treatment intervals in patients with continuing GVHD. These findings suggest that PBM therapy represents an additional approach for continuing management of oral cGVHD and that the frequency of treatment should be individualized for each patient to provide best control of oral findings. In one case weekly PBM treatment was continued, while in others, management on a monthly or bimonthly basis was associated with control of the oral condition. PBM may be individualized and provided based upon best control of the symptoms and signs of oral GVHD.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Terapia por Luz de Baja Intensidad / Enfermedad Injerto contra Huésped / Enfermedades de la Boca Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Terapia por Luz de Baja Intensidad / Enfermedad Injerto contra Huésped / Enfermedades de la Boca Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos